The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age

References

• Visser JA, de Jong FH, Laven JSE, Themmen APN. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 2006;131:1–9.
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Visser JA, Laven JSE, Broer SL, Themmen APN, Fauser BC. Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab 2008;19:340–347.
   PubMed Web of Science ®Google Scholar
• Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008;14:367–378.
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of Anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicle arrest. J Clin Endocrinol Metab 2003;88:5957–5962.
   PubMed Web of Science ®Google Scholar
• Laven JSE, Mulders AGMGJ, Visser JA, Themmen AP, de Jong FH, Fauser BCJM. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318–323.
   PubMed Web of Science ®Google Scholar
• Al-Qahtani A, Groome NP. Editorial: anti-müllerian hormone: cinderella finds new admirers. J Clin Endocrinol Metab 2006;91:3760–3762.
   PubMedGoogle Scholar
• Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, editors. Polycystic ovary syndrome, Boston: Blackwell Scientific Publications;1992. pp 377–384.
   Google Scholar
• Broekmans FJ, Knauff EAH, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BCJM. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 2006;113:1210–1217.
   PubMed Web of Science ®Google Scholar
• Balasch J, Fábregues F, Creus M, Puerto B, Peñarrubia J, Vanrell JA. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum Reprod 2001;16:652–656.
   PubMed Web of Science ®Google Scholar
• Peñarrubia J, Fábregues F, Manau D, Creus M, Casals G, Casamitjana R, Carmona F, Vanrell JA, Balasch J. Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment. Hum Reprod 2005;20:915–922.
   PubMed Web of Science ®Google Scholar
• Vidal J, Morinigo R, Codoceo VH, Casamitjana R, Pellitero S, Gomis R. The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects. Int J Obes 2005;29:668–674.
   Google Scholar
• Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod 2006;21:1884–1893.
   PubMed Web of Science ®Google Scholar
• Morínigo R, Casamitjana R, Delgado S, Lacy A, Deulofeu R, Conget I, Barceló-Batllori S, Gomis R, Vidal J. Insulin resistance, inflammation, and the metabolic syndrome following Roux-en-Y gastric bypass surgery in severely obese subjects. Diabetes Care 2007;30:1906–1908.
   PubMedGoogle Scholar
• Rowe PJ, Comhaire FH, Hargreave TB, Mellows H. Female partner. In: Rowe PJ, Comhaire FH, Hargreave TB, Mellows H, editors. WHO manual for the standardized investigation and diagnosis of the infertile couple, Cambridge, UK: Press Syndicate of the University of Cambridge; 2000. pp 40–67.
   Google Scholar
• Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005;83:1343–1345.
   PubMed Web of Science ®Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 4):S221–S223.
   Google Scholar
• Escobar-Morreale HF. Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother 2008;9:2295–3008.
   PubMedGoogle Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril 2006;86(Suppl 4):S187–S193.
   Google Scholar
• Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323–327.
   PubMed Web of Science ®Google Scholar
• Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:E238–E243.
   PubMed Web of Science ®Google Scholar
• Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008;198:670.e1–670.e7.
   PubMed Web of Science ®Google Scholar
• La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. Müllerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970–972.
   PubMed Web of Science ®Google Scholar
• La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol 2006;64:603–610.
   PubMed Web of Science ®Google Scholar
• Chu MC, Carmina E, Wang J, Lobo RA. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B. Fertil Steril 2005;84:1685–1688.
   PubMed Web of Science ®Google Scholar
• Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerina-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005;83:130–136.
   PubMedGoogle Scholar
• Pigny P, Jonard S, Roberts Y, Dewailly D. Serum anti-müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941–945.
   PubMed Web of Science ®Google Scholar
• Pellat L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H. Granulosa cell production of antimu¨llerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92:240–245.
   PubMedGoogle Scholar
• Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 2007;87:870–875.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update 2009;15:57–68.
   PubMed Web of Science ®Google Scholar
• Pache TD, Wladimiroff JW, de Jong FH, Hop WC, Fauser BC. Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil Steril 1990;54:638–642.
   PubMedGoogle Scholar
• Scheffer GJ, Broekmans FJM, Dorland M, Habbema JDF, Looman CWN, te Velde ER. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril 1999;72:845–851.
   PubMed Web of Science ®Google Scholar
• Hendriks DJ, Mol BWJ, Bancsi LFJMM, te Velde ER, Broekmans FJM. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 2005;83:291–301.
   PubMed Web of Science ®Google Scholar